CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 51 enrolled
Drug / intervention
Recombinant Human Papillomavirus Nonavalent Vaccine +3 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03036930
NCT03036930Phase 2Active

Immunogenicity of Nonavalent HPV Vaccine Administered Prior to Renal Transplantation in Adults: A Prospective, Single-Arm, Multi-Center Clinical Trial

National Cancer Institute (NCI)·interventional·Posted Jan 31, 2017·Updated May 29, 2026

In Brief

A Phase 2 clinical trial evaluating Biospecimen Collection, HPV Self-Collection, and 2 other interventions for Human Papillomavirus Infection and Human Papillomavirus-Related Carcinoma. Active but no longer recruiting, targeting 51 participants across 6 sites.

Detailed Summary

This phase II trial studies whether the nonavalent human papillomavirus vaccine given to adults prior to kidney transplantation can help the body build and maintain an effective immune response during the post-transplant period when they receive immunosuppressive drugs to prevent transplant rejection. This study will help inform our scientific understanding about vaccine-induced immune responses among immunosuppressed individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2Active
20172018201920202021202220232024202520262027
First PostedJan 31, 2017
Enrollment StartJun 23, 2017
Primary CompletionMar 4, 2024
Study CompletionMar 10, 2027
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 9.4 years ago

Interventions

Biospecimen Collectionprocedure

Undergo collection of blood samples

HPV Self-Collectionprocedure

Undergo self-collection of vaginal/cervical samples

Questionnaire Administrationother

Ancillary studies

Recombinant Human Papillomavirus Nonavalent Vaccinebiological

Given IM